
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd has exhibited significant growth potential, as evidenced by a greater than 50% increase in equipment utilization since the establishment of its investment arrangement. The company is benefiting from strategic investments that are poised to enhance revenue growth and is witnessing a growing acceptance of pay-per-use models along with potential demand from neurologist specialists. Additionally, the optimized clinic infrastructure for Deep TMS therapy positions BrainsWay favorably alongside existing treatment options, suggesting a robust market acceptance and diversification of revenue streams.
Bears say
The negative outlook on BrainsWay's stock is primarily driven by several fundamental risks associated with its business model, particularly the slower-than-projected uptake of Deep TMS systems. Additionally, the company faces challenges in expanding reimbursement and market access, which could hinder revenue growth. Furthermore, the inability to advance its technology into other therapeutic indications, along with potential long-term dilution risk, raises concerns about the company’s future financial stability and growth potential.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares